Demant A/S (WILYY) Stock Forecast & Price Target

$17.93 0.00 (0.00%)

(As of 12/20/2024 ET)

Demant A/S - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 3 Analyst Ratings

Sell
0

Hold
1

Buy
2

Based on 3 Wall Street analysts who have issued ratings for Demant A/S in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 1 has given a hold rating, and 2 have given a strong buy rating for WILYY.

Consensus Price Target

N/A

Get the Latest News and Ratings for WILYY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Demant A/S and its competitors.

WILYY Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)	4 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	N/A	N/A	N/A	N/A
Forecasted Upside	N/A	N/A	N/A	N/A
Consensus Rating	Buy	Buy	Buy	Moderate Buy

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

WILYY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

WILYY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Demant A/S Stock vs. The Competition

Type	Demant A/S	Medical Companies	S&P 500
Consensus Rating Score	3.33	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	N/A	25,828.59% Upside	14.54% Upside
News Sentiment Rating	Neutral News See Recent WILYY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating
10/21/2024	The Goldman Sachs Group 2 of 5 stars	R. Felton Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/13/2024	Hsbc Global Res 0 of 5 stars	R. Department Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/28/2024	UBS Group 4 of 5 stars	G. Doyle Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Overweight
8/8/2023	Nordea Equity Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
5/12/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
5/8/2023	Handelsbanken Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
3/28/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Equal Weight
2/8/2023	Danske Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
1/25/2023	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral
1/25/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:07 PM ET.

WILYY Forecast - Frequently Asked Questions

: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Demant A/S in the last year. There is currently 1 hold rating and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" WILYY shares.
: According to analysts, Demant A/S's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.
: Over the previous 90 days, Demant A/S's stock had 1 upgrade by analysts.
: Demant A/S has been rated by research analysts at The Goldman Sachs Group in the past 90 days.
: Analysts like Demant A/S more than other "medical" companies. The consensus rating for Demant A/S is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how WILYY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

This page (OTCMKTS:WILYY) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Demant A/S (WILYY) Stock Forecast & Price Target